Evidence map›Paper›PMID 39340365›Full record

ArticleJournal of biomedical materials research. Part B, Applied biomaterials2024

Molecular Biomarkers for In Vitro Thrombogenicity Assessment of Medical Device Materials.

Mehulkumar Patel, Anna Parrish, Carlos Serna, Megan Jamiolkowski, Keerthana Srinivasan, Richard Malinauskas, Qijin Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biomedical materials research. Part B, Applied biomaterials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mehulkumar PatelDivision of Applied Mechanics, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Anna ParrishDivision of Applied Mechanics, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Carlos SernaDivision of Applied Mechanics, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Megan JamiolkowskiDivision of Applied Mechanics, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Keerthana SrinivasanDivision of Applied Mechanics, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Richard MalinauskasDivision of Applied Mechanics, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Qijin LuDivision of Applied Mechanics, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.ORCID 0000-0002-3004-9433

Funding

Intramural FDA HHS FD999999U.S. Food and Drug Administration
6 · The paper itself

Abstract

To develop standardized in vitro thrombogenicity test methods for evaluating medical device materials, three platelet activation biomarkers, beta-thromboglobulin (β-TG), platelet factor 4 (PF4), soluble p-selectin (CD62P), and a plasma coagulation marker, thrombin-antithrombin complex (TAT), were investigated. Whole blood, drawn from six healthy human volunteers into Anticoagulant Citrate Dextrose Solution A was recalcified and heparinized over a concentration range of 0.5-1.5 U/mL. The blood was incubated with test materials with different thrombogenic potentials for 60 min at 37°C, using a 6 cm

Indexed as

beta-ThromboglobulinBiomarkersPlatelet ActivationPlatelet Factor 4P-SelectinAdultAntithrombin IIIBiocompatible MaterialsFemaleHeparinHumansMaleMaterials TestingPeptide HydrolasesThrombosisAntithrombin IIIantithrombin III-protease complexbeta-ThromboglobulinBiocompatible MaterialsBiomarkersHeparinPeptide HydrolasesPlatelet Factor 4P-SelectinSELP protein, humanbiomaterialscoagulationhemocompatibilitymolecular markersplatelet activationthrombogenicity

Identifiers

PMID39340365
PMCPMC11661467

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.